Natco Pharma to enhance total investment in eGenesis to $25 million
Natco Pharma is significantly increasing its investment in eGenesis, a clinical-stage biotechnology company, to nearly $25 million through its subsidiaries. This funding supports eGenesis's pioneering work in developing gene-edited pig organs for transplantation, aimed at alleviating the critical shortage of human organs.
Why it matters
This substantial investment could accelerate the development and adoption of xenotransplantation, offering a groundbreaking solution to organ failure and marking a significant advancement in medical science and patient care.
Natco Pharma is deepening its investment in clinical-stage biotechnology company eGenesis, increasing its planned investment through subsidiaries to $16.7 million from the earlier announced $14 million.
Under the revised investment plan, Natco Pharma’s Canadian subsidiary will invest $13.7 million, while Natco Pharma USA LLC will contribute $3 million. On completion of the transaction, Natco’s total investment in eGenesis will rise to $24.7 million.
Natco, through its Canadian subsidiary, had in 2024 invested $8 million in eGenesis, which is developing porcine solid organ donors using its multiplex gene-editing and genome-engineering platform, with the aim of addressing the shortage of human organs available for patients suffering from organ failure.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in